Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

Back to Search
Print
Bookmark Trial

NCT01726023

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Research Site
Baotou, , , China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Complicated Intra-abdominal Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patient must be 18 to 90 years of age, inclusive,

- Female patients can participate if they are surgically sterilized or postmenopausal for at least 1 year or her sexual partner has had a vasectomy

- Female of childbearing potential has had normal menstrual periods for 3 months and negative serum pregnancy test and agree to practice highly effective methods of birth control during treatment and for at least 7 days after last dose

- Intraoperative/postoperative enrollment with visual confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis

- Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory indicators; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12
hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other
intra-abdominal processes in which primary etiology is not likely to be infectious


- Patient has abdominal wall abscess or bowel obstruction without perforation or
ischemic bowel without perforation


- Patients whose surgery will include staged abdominal repair, or "open abdomen"
technique, or marsupialization


- Patient has suspected intra-abdominal infections due to fungus, parasites, virus or
tuberculosis


- Patient is considered unlikely to survive the 6- to 8-week study period or has a
rapidly progressive or terminal illness, including septic shock that is associated
with a high risk of mortality

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Complicated Intra-abdominal InfectionCompare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
NCT01726023
  1. Baotou,
  2. Beijing,
  3. Changsha,
  4. Chengdu,
  5. Chongqing,
  6. Fuzhou,
  7. Guangzhou,
  8. Guilin,
  9. Haikou,
  10. Hebei,
  11. Jiangyin,
  12. Liaocheng,
  13. Nan Chang,
  14. Shanghai,
  15. Tianjin,
  16. Urumqi,
  17. Wenzhou,
  18. Wuxi,
  19. Xi'an,
  20. Ansan-si,
  21. Anyang-si,
  22. Busan,
  23. Cheongju-si,
  24. Daejeon,
  25. Gwangju,
  26. Jinju-si,
  27. Seoul,
  28. Wonju-si,
  29. Hanoi,
  30. Hochiminh,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Complicated Intra-Abdominal InfectionImpact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
NCT00929643
  1. Haidari, Athens
  2. Holargos, Athens
  3. Marousi, Athens
  4. N. Ionia, Athens
  5. Peireus, Athens
  6. Rio, Patras
  7. Herakleion, Vrete
  8. Athens,
  9. Athens,
  10. Thessaloniki,
  11. Thessaloniki,
  12. Thessaloniki,
  13. Thessaloniki,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Complicated Intra-Abdominal InfectionCompare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
NCT01499290
  1. Chula Vista, California
  2. San Diego, California
  3. Saint Louis, Missouri
  4. Somers Point, New Jersey
  5. Córdoba,
  6. Rosario,
  7. Ruse,
  8. Varna,
  9. Zagreb,
  10. Decin,
  11. Hradec Kralove,
  12. Jihlava,
  13. Olomouc,
  14. Praha 10,
  15. Praha 5,
  16. Teplice,
  17. Budapest,
  18. Székesfehérvár,
  19. Bangalore,
  20. Pune,
  21. Trivandrum,
  22. Vadodara,
  23. Hadera,
  24. Haifa,
  25. Riga,
  26. Alor Setar,
  27. Durango,
  28. Guadalajara, Jalisco,
  29. Mexico City,
  30. Enschede,
  31. s-Hertogenbosch,
  32. Arequipa,
  33. Cercardo de Lima,
  34. Lima,
  35. Trujillo,
  36. Cluj-Napoca,
  37. Iasi,
  38. Kemerovo,
  39. Moscow,
  40. Saratov,
  41. Vsevolozhsk,
  42. Pretoria,
  43. Alcorcón,
  44. Elche,
  45. Sabadell(Barcelona),
  46. Kaohsiung,
  47. Taichung,
  48. Tainan,
  49. Taipei,
  50. Bangkok,
  51. Khon Kaen,
  52. Phisanulok,
  53. Dnipropetrovsk,
  54. Ivano-Frankivsk,
  55. Kharkov,
  56. Kyiv,
  57. Zaporizhzhya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Official Title  ICMJE A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Brief Summary The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Detailed Description A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Complicated Intra-abdominal Infection
Intervention  ICMJE
  • Drug: Ceftazidime-avibactam
    Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
  • Drug: metronidazole
    Metronidazole 500mg/100ml solution for infusion
  • Drug: Meropenem
    Meropenem powder for solution for infusion 1000mg
Study Arms  ICMJE
  • Experimental: Ceftazidime-Avibactam plus metronidazole
    Interventions:
    • Drug: Ceftazidime-avibactam
    • Drug: metronidazole
  • Active Comparator: Meropenem
    Intervention: Drug: Meropenem
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 15, 2015)		486
Original Estimated Enrollment  ICMJE
 (submitted: November 9, 2012)		404
Actual Study Completion Date  ICMJE March 2015
Actual Primary Completion Date March 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patient must be 18 to 90 years of age, inclusive,
  • Female patients can participate if they are surgically sterilized or postmenopausal for at least 1 year or her sexual partner has had a vasectomy
  • Female of childbearing potential has had normal menstrual periods for 3 months and negative serum pregnancy test and agree to practice highly effective methods of birth control during treatment and for at least 7 days after last dose
  • Intraoperative/postoperative enrollment with visual confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis
  • Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory indicators; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion Criteria:

  • Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious
  • Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation
  • Patients whose surgery will include staged abdominal repair, or "open abdomen" technique, or marsupialization
  • Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis
  • Patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China,   Korea, Republic of,   Vietnam
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01726023
Other Study ID Numbers  ICMJE D4280C00018
2011-003893-97
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Paul A Newell, MBBS, MRCPAstraZeneca
PRS Account Pfizer
Verification Date September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP